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Background: Early stages of esophageal cancer lack a specific symptom, a reliable biomarker and accurate non-invasive diagnostic 
modalities prompting the pressing need for identification of a marker for early diagnosis of this disease.
Methods: In the present study we investigated the levels of circulating and tissue mRNAs of Oct-3/4, Sox-2, Nanog and Bmi-1 in 
esophageal cancer patients using Reverse-Transcription Polymerase Chain Reaction (RT-PCR) with the aim of evaluating their potential 
as minimally invasive diagnostic markers.
Result: Increased transcript levels of Oct-4, Sox-2, Bmi-1 and Nanog were detected in (92%), (95%), (75%) and (67%) of the esopha-
geal cancer tissues, respectively as compared with the matched distant normals.
Conclusion: Interestingly, most of the preneoplastic tissues exhibited increased transcript levels of these stemness markers suggesting 
their role in early stages of esophageal tumorigenesis. Furthermore, the detection of elevated levels of circulating mRNAs of Oct-4 and 
Nanog in sera of esophageal cancer patients emphasizes their potential as minimally invasive diagnostic markers for esophageal 
cancer.
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Introduction
Human esophageal cancer occurs worldwide with a 
variable geographic distribution and ranks eighth in 
order of occurrence and sixth as the leading cause of 
cancer mortality, affecting men more than women.1 
At diagnosis, nearly 50% of cases have cancer that 
extends  beyond  the  primary  locoregional  confines 
and 75% of patients requiring surgery have proximal 
lymph  node  metastasis.  At  this  stage,  therapeutic 
modalities are limited in their success. Detecting can-
cers in early stages even in the premalignant state, 
means  that  current  or  future  treatment  modalities 
might have a higher likelihood of a true cure. In spite 
of the use of modern surgical techniques combined 
with various adjuvant treatment modalities, such as 
radiotherapy  and  chemotherapy,  the  overall  5-year 
survival  rate  of  esophageal  cancer  patients  still 
remains  less  than  10%.  Hence,  early  detection  of 
esophageal cancer lacks a specific symptom, a spe-
cific biomarker and accurate and reliable diagnostic, 
non-invasive modalities. Traditional methods of treat-
ing cancer include use of invasive or mildly invasive 
diagnostic tests, biopsy, and histological examination 
and so on. The invasive, unpleasant and inconvenient 
nature of the current diagnostic procedures limits the 
application of till date proven tumor markers. Hence, 
there is a pressing need for establishment of novel 
non-invasive biomarkers for early tumor diagnosis 
and monitoring response to therapy and prognosis.
Stem cell related genes, Oct 3/4, Sox2, Nanog and 
Bmi-1 are the factors responsible for the maintenance 
of the proliferation and pluripotent character in the 
Embryonic  Stem  Cells.  Cancer  cells,  especially  in 
poorly differentiated or undifferentiated tumors, have 
been characterized by many phenotypic traits similar 
to undifferentiated embryonic cells, indicating that 
stem cell related genes viz. Oct3/4, Sox2, Nanog and 
Bmi-1 may be expressed in solid tumors.
Oct-4,  belongs  to  the  POU  (Pit-Oct-Unc)  tran-
scription factor family.2 The POU family of transcrip-
tion factors can activate the expression of their target 
genes through binding an octameric sequence motif 
of an AGTCAAAT which is a consensus sequence.3a 
This gene encodes a transcription factor containing a 
POU homeodomain. Oct-4 plays a key role in the 
maintenance of proliferation potential of embryonic 
stem cells as well as the human adult stem cells.4 
Moreover, Pesce and Scholar, 1990 have shown Oct-4 
to be downregulated in all the differentiated somatic 
cell types in vitro and in vivo.3b
Sox (SRY box) genes have been identified through 
their homology to the high mobility group (HMG) box 
(79 amino acids) of sex-determining factor SRY. The 
Sox2, a member of the Sox gene family which is an 
intronless gene encodes a group of transcription factors 
that  are  characterized  by  a  highly  conserved  high- 
mobility group (HMG) domain.5 These genes are found 
throughout  the  animal  kingdom,  are  expressed  in  a 
restricted  spatial-temporal  pattern,  and  play  critical 
roles in stem cell biology, organogenesis, and animal 
development.6,7 For example, overexpression of Sox2 in 
mouse  neural  stem  cells  blocks  their   differentiation. 
Recently,  SOX  transcription  factors  have  been 
found to be associated with human cancers.8
Nanog  is  another  transcription  factor  critically 
involved with self-renewal of undifferentiated embry-
onic stem cells. In humans, this protein plays a criti-
cal role in regulating the cell fate of the pluripotent 
inner  cell  mass  during  embryonic  development.9 
In vitro, Nanog mRNA is enriched in pluripotent cell 
lines such as embryonic stem, embryonic germ, and 
embryonic carcinoma cells but not in adult tissues. 
On differentiation of these pluripotent cells, Nanog 
expression is down-regulated. Takahashi et al 2007 
reported that Nanog, works in concert with Oct-4 and 
Sox-2 to maintain pluripotency.10
Bmi-1 polycomb ring finger oncogene, also known 
as Bmi-1, is a protein which in humans is encoded by 
the  BMI1  gene.11  The  mRNA  transcribed  from 
Bmi-1 gene is linear and 3251 bp in length and Bmi1 
has a RING finger at the N-terminus and a central 
helix-turn-helix domain.12 Bmi-1 has been reported to 
regulate p16 and p19, the cell cycle inhibitor genes 
and hence act as the oncogene rendering abnormal 
proliferative ability. Bmi-1 is necessary for efficient 
self-renewing cell divisions of adult hematopoietic 
stem cells as well as adult peripheral and central ner-
vous system neural stem cells and is a downstream 
target in the Hedgehog (Hh) pathway.
Previous  studies  have  demonstrated  that  many 
cancers express these genes and that their expression 
appears to be important for cancer cell survival. The 
Oct3/4 and Sox2 genes have also been shown to be 
expressed  in  human  tumors  including  pancreatic, 
breast, esophageal and gastric carcinomas.13 Recent 
studies have shown the overexpression of Bmi-1 in expression of stem cell related genes in eScc patients
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many somatic solid tumors such as colon carcinoma,14 
non  small  lung  cancer,15  breast  cancer,16  head  and 
neck cancer17 and gastric carcinoma.18 He et al 2009 
have shown its overexpression in ESCC.19 Although 
NANOG is generally found to be expressed in germ 
cell  tumors20  as  well  as  in  somatic  tumors  like 
breast21,22 cervix,23 oral cavity,24 kidney,25 and ovary,26 
however, there are reports of its expression in esopha-
geal cancer. Recently, microarray analysis of “Tip”-
Side Population cells of esophageal cancer cell lines 
showing stem cell like characteristics revealed differ-
ential  expression  of  several  important  stem  cell– 
related genes viz. Oct-4, Sox-2, Bmi-1, and ZFX.27 
Therefore, it might be expected that cancer cells will 
express genes in common with the very early embry-
onic  cells,  especially  genes  specifically  associated 
with deprogramming, return to the undifferentiated 
and proliferative stem cell state, and the maintenance 
of that state. Moreover, the identification of circulat-
ing levels of these genes in sera of ESCC patients 
may be instrumental in development of these makers 
as a diagnostic tool for the early diagnosis of esopha-
geal cancer. Thus, keeping in view the above men-
tioned facts the aim of the present study is to analyze 
the expression of stem cell markers viz. Oct-4, Sox-2, 
Bmi-1 and Nanog in tumor and sera in the ESCCs and 
evaluate their potential as minimally invasive blood 
based markers. To the best of our knowledge, this is 
the  first  study  analyzing  the  levels  of  circulating 
mRNAs of these genes in sear of esophageal squamous 
cell carcinoma patients. It is also the first report show-
ing the expression of Nanog in ESCCs.
Materials and Methods
Patients and clinicopathological data 
collection, tissue and blood specimens
Tumor and matched distant nonmalignant esophageal 
tissue biopsy specimens from a distal site were col-
lected  from  33  esophageal  diagnostic  biopsies  of 
patients who underwent endoscopy in Department of 
Gastroenterology, All India Institute of Medical sci-
ences,  New  Delhi,  India  with  the  prior  consent  of 
patients. This study was approved by the institutional 
human ethics committee prior to its   commencement. 
The sample collection was carried out for a period 
of 8 months from October 2009 to June 2010. The 
samples  were  collected  and  immediately  snap 
frozen in liquid N2 and stored at −80 °C till further use. 
The clinical and pathological data were recorded in a 
predesigned  Performa  including  age,  gender,  and 
  alcohol  consumption,  tobacco  and  histological 
  differentiation.  The  tumors  were  histopathologically 
graded as preneoplastic (8) and neoplastic (25). Of the 
33 endoscopic biopsies collected 25 showed evidence 
of ESCC of different grade, 5 were hyperplastic and 
3 showed evidence of dysplasia. Blood samples were 
collected from 17 out of 33 ESCC patients enrolled in 
the study whose tumors were analysed for the expres-
sion of stem cell related genes. Blood samples were 
also collected from 8 normal subjects. The sera was 
separated and stored at −80 °C till further use.
The esophageal squamous cell carcinoma (ESCC) 
cell line TE13 was used as positive control for gene 
expression studies. The cell line was developed from 
squamous cell carcinoma of esophageal origin28 and 
was a kind gift from Dr. Pierre Haiuant, IARC, France. 
TE13 cells were cultured in a 1:1 mixture of Rose 
Park Memorial Institute (RPMI) supplemented with 
10% FBS. Cells were grown in monolayer cultures in 
a humidified incubator (5% carbon-dioxide, 95% air) 
at 37 °C.
rnA Isolation from tissue specimens
Total RNA was isolated from the tissue samples using 
the RNA easy minikit (Qiagen, Denmark). Briefly, 
the lysate were prepared using the lysis buffer fol-
lowed  by  the  addition  of  ethanol  to  provide  ideal 
binding conditions. The lysate was then loaded onto 
the RNAeasy Mini spin column. RNA binds and all 
contaminants  were  efficiently  washed  away  in  the 
subsequent washing steps. Pure, concentrated RNA 
was eluted in RNase free water.
rnA Isolation from sera samples
Total RNA was isolated from the sera samples using 
QIAamp Viral RNA minikit (Qiagen, Denmark) fol-
lowing the manufacturer’s protocol. Briefly, the sam-
ples  were  first  lysed  under  highly  denaturing 
conditions to inactivate RNAses and to ensure the 
isolation of intact circulating RNA. Buffering condi-
tions were then adjusted to provide optimum binding 
of the RNA to QIAamp membrane and then sample 
were loaded on the QIAamp spin column. The RNA 
bound to the membrane and the contaminants were 
washed away using two different buffers. RNA was 
eluted in RNAase free water.Bahl et al
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The  RNA  isolated  from  both  tissue  and  sera 
  samples were quantified by spectrophotometry, absor-
bance taken at 260 nm. The RNA obtained from tis-
sue and sera samples were in the range of (1–2 µg/µL) 
and (0.5–1 µg/µL), respectively.
Reverse Transcription polymerase 
chain Reaction (RT-pcR)
The first strand cDNA was reverse transcribed from 
DNA free total RNA obtained from esophageal tis-
sues and sera using random hexamers (Fermentas, 
Canada) and MMLV reverse trancriptase (Fermentas, 
Canada).
The cDNA thus obtained was PCR amplified using 
the gene specific primer sets for Oct-4, Sox-2, Bmi-1 
and Nanog (Table 1). β-Actin was used as a control to 
optimize the amounts of cDNA generated from each 
sample. PCR amplification was carried out in a total 
volume of 20 µL containing 3 µL reverse transcribed 
cDNA, 1x PCR buffer, 0.3 mM dNTPs, 0.5 µM each 
primer,  and  1  unit  of Taq  polymerase  (Fermentas, 
Canada). After 5 min of initial denaturation, 35 ampli-
fication cycles of 1 min at 94 °C, 1 min at specific 
annealing temperature (Table 1), and 1 min. at 72 °C 
were carried out followed by a 10 min elongation at 
72 °C. The PCR products were then electrophoresed 
on 1% agarose gel and the bands of specific sizes 
were observed.
Densitometric  analysis  was  carried  out  using 
Image J software to compare the expression of these 
mRNAs in ESCCs and the matched distant non malig-
nant esophageal tissue biopsies. For individual sam-
ples, the integrated intensity value of each band (sum 
of all the pixel intensity values in a given band) was 
determined  and  the  background  was  subtracted. 
  Normalization was achieved by dividing the corrected 
integrated density value of the gene in each sample by 
corrected integrated density value of beta-actin gene 
in the corresponding sample. The ratio was consid-
ered as arbitrary units. The expression levels of Oct-4, 
Sox-2, Bmi-1 and Nanog in each tissue is represented 
by a histogram.
real time rT-Pcr
Real-time RT-PCR was performed with OPTICON 2 
Real time PCR system (BioRad) in a total volume 
25 µL containing 0.5 µM of each primer, 12.5 µL 
SYBR® Premix Ex Taq SYBR green mix (Takara, 
Japan) and 2.5 µL of cDNA. PCR reactions were pre-
pared and heated to 95 °C for 1 minutes followed by 
40 cycles of denaturation at 95 °C for 10 seconds, 
annealing at specific Tm for 1 min, and extension at 
72 °C for 1 minute. Fluorescence detection was per-
formed at the end of each extension step. The cycle 
threshold (Ct) was recorded for each sample and 5 s 
RNA was used as the endogenous control for data 
normalization.  Relative  expression  was  calculated 
using comparative CT method. The quantitative real 
time RT-PCR amplification products were analyzed 
by melting curve analysis.
Statistical analysis
Statistical analyses of the data were performed using 
SPSS software version 13.0 (SPSS, Chicago). The 
associations between the Oct-4, Sox-2, Nanog and 
Bmi-1  and  the  clinicopathalogical  parameters  of 
the  ESCC  patients  were  examined  using  the 
Chi-Square test. A P-value of 0.05 has been defined 
Table 1. Parameters for rT-Pcr analysis of stem cell related genes.
Gene Annealing  
temperature (°c)
primer combination product length (bp)
Oct-4 58 °c 5′ gAg gAg Tcc cAg gAc ATc AA 3′ 429 bp
5′ AcA cTc ggA ccA cAT ccT Tc 3′
Sox-2 64 °c 5′ gcc Tgg gcg ccg AgT ggA 3′ 443 bp
5′ ggg cgA gcc gTT cAT gTA ggT cTg 3′
nanog 58 °c 5′ gggcgAgccgTTcATgTAggTcTg 3′ 438 bp
5′ ATTTcATTcgcTggTTcTgg 3′
Bmi-1 57 °c 5′ cAg cAA TgA cTg TgA Tgc AcT 3′ 799 bp
5′ gcc cAA Tgc TTA TgT ccA cT 3′
βactin 62 °c 5′-cAg ccA TgT Acg TTg cTA Tcc Ag-3′ 646 bp
5′-gTT Tcg Tgg ATg ccA cAg gAc-3′expression of stem cell related genes in eScc patients
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as the criterion for the statistical significance. All the 
P-values reported were 2-tailed.
Results
The  expression  of  stem  cell  related  genes  Oct-4, 
Sox-2, Bmi-1, Nanog was analyzed in ESCCs (25), 
preneoplastic esophageal tissues (8) and matched dis-
tant non malignant tissues of the esophageal biopsy. 
As, there is heterogeneity in the origin of cells present 
in the endoscopic biopsy specimen, the expression of 
Oct-4, Sox-2, Bmi-1 and Nanog was analysed in the 
esophageal cancer cell line (TE13) as well. Stem cell 
related genes analysed in this study were expressed in 
the TE13 cell line indicating there expression occurs 
in the tumor cells (data not shown).
Elevated levels of Oct-4 mRNA were observed 
23/25  (92%)  in  of  the  ESCC  tissues  (Table  2). 
  Interestingly,  5/6  (83.3%)  hyperplastic  tissues 
showed overexpression of Oct-4 mRNA as com-
pared to distant non malignant tissues which show 
low or no detectable expression suggesting its role 
in early stages of esophageal tumoriogenesis. One 
of the two dysplastic tissues showed expression of 
Oct-4.   Figure 1A shows the elevated transcript lev-
els of Oct-4 in representative ESCCs and matched 
distant nonmalignant esophageal tissues with refer-
ence to the house keeping gene β-actin shown in 
(Fig. 1G). Densitometric analysis showed evident 
increase in its expression in preneoplastic and neo-
plastic   cancerous tissues as compared to the matched 
non  malignant  esophageal  tissues  (Fig.  2A). 
  Moreover, 12/17 (70%) of the ESCC patients’ sera 
samples show expression of Oct-4 mRNA as com-
pared to no detectable expression in sera of normal 
subjects (Fig. 1B).
No significant correlation was observed between 
Oct-4 gene and clinicopathological parameters. All 
the  sera  specimens  showing  overexpression  of 
Oct-4  mRNA  also  showed  tissue  positivity  for  its 
gene expression further corroborating the fact that 
presence of Oct-4 mRNA in patients sera is from the 
tumor tissue.
Of the 25 ESCCs, Sox-2, Nanog and Bmi-1 expres-
sion could be analysed in 22, 21 and 20 samples respec-
tively due to less quantity of the rest of the samples.
Increased transcript levels of Sox-2 were observed 
in 21/22 (95%) of the ESCC tissues (Table 2). Of the 
five  hyperplastic  tissues  analysed  4  (80%)  tissues 
showed  the  overexpression  of  the  Sox-2  mRNA  as 
compared to f non malignant tissue which showed no 
or low detectable expression hence it could be involved 
in the early phase of tumoriogenesis with reference to 
Housekeeping  gene  β-actin  shown  in  (Fig.  1G). 
  Figure  1C  shows  the  elevated  transcript  levels  of 
Sox-2 in representative ESCCs and matched distant 
nonmalignant esophageal tissues. Densitometric anal-
ysis showed evident increase in its expression in pre-
neoplastic and neoplastic cancerous tissues as compared 
to  the  matched  non  malignant  esophageal  tissues 
(Fig. 2B). Sox-2 did not show significant correlation 
with any of the clinicopathological parameters.
Overexpression of Nanog was observed in 14/21 
(67%)  of  the  ESCC  tissues  (Table  2).  Figure  1E 
shows the elevated transcript levels of Nanog in rep-
resentative ESCCs and matched distant nonmalig-
nant  esophageal  tissues.  Densitometric  analysis 
showed evident increase in its expression in hyper-
plastic and neoplastic cancerous tissues as compared 
to  the  matched  non  malignant  esophageal  tissues 
(Fig.  2C).  Interestingly,  4/5  (80%)  hyperplastic 
Table 2. Overexpression of Stem cell related mrnA transcripts in human eSccs, preneoplastic and normal esophageal 
epithelium.
Tissue type Oct-4 positive n (%) sox-2 positive n (%) nanog positive n (%) Bmi-1 positive n (%)
eScc 23/25 (92) 21/22 (95) 14/21 (67) 15/20 (75)
Preneoplasia (hyperplasia 
and Dysplasia)
5/8 (63) 4/5 (80) 4/5 (80) 2/3 (67)
Age
 # 40 26/29 (90) 22/24 (92) 15/23 (65) 15/21 (71)
 . 40 3/4 (75) 2/3 (67) 3/3 (100) 2/2 (100)
gender
  Male 19/22 (86.3) 15/18 (83.3) 12/17 (70.5) 10/15 (66.6)
  Female 11/11 (100) 9/9 (100) 6/9 (67) 7/8 (88)Bahl et al
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Figure 1. representative 1% agarose showing the rT-Pcr analysis of stem cell related genes in representative esophageal tissues. (A) shows a 429 bp 
Oct-4 amplicon in 4 distant normal tissues (n1-n4) and 4 eScc tissues (c1-c4). (B) shows a 429 bp Oct-4 amplicon in 7 eScc patients’ sera (S1-S7) 
and 1 normal subject sera (nS). (c) shows a 438 bp Sox-2 amplicon in 4 distant normal tissues (n1-n4) and 4 eScc tissues (c1-c4). (D) shows a 443 bp 
nanog amplicon in 4 distant normal tissues (n1-n4) and 4 eScc patients (c1-c4). (e) shows a 443 bp nanog amplicon in 8 eScc patients’ sera (S1-S8) 
and 1 normal subject sera (nS). (F) shows a 799 bp Bmi-1 amplicon in 3 distant normal tissues (n1-n3) and 4 eScc patients (c1-c3). (G) shows a 646 bp 
amplification of β-actin in the respective esophageal tissue samples.
patients  showed  the  overexpression  of  the  Nanog 
mRNA transcripts as compared to the distant non 
malignant tissues which showed no or low detectable 
expression level which could be the harbinger of this 
gene involved in early stages of tumirogenesis with 
reference to the House keeping gene β-actin shown 
in (Fig. 1G). Moreover, 10/17 (60%) of the ESCC 
sera samples shows expression of Nanog mRNA as 
compared to no detectable expression in sera of nor-
mal subjects (Fig. 1F). No significant correlation was 
observed between the Nanog expression and any of 
the clinicopathological parameter.
Elevated expression levels of Bmi-1 was found in 
the  15/20  (75%)  of  the  tissues  (Table  2,  Fig.  1F). 
  Densitometric analysis showed evident increase in its 
expression in preneoplastic and neoplastic cancerous 
tissues  as  compared  to  the  matched  non  malignant 
esophageal tissues (Fig. 2E). 2/3 (67%) of the Bmi-1 
preneoplastic  lesions  showed  increased  Bmi-1 
  expression. There was no significant correlation between 
Bmi-1 expression the clinicopathological parameter.
Quantitative real time PCR performed in represen-
tative  esophageal  samples  further  validated  the 
increased expression of stem cell related genes viz. 
Oct-4, Sox-2, Bmi-1 and Nanog in ESCCs as com-
pared to matched non malignant esophageal tissues 
using comparative CT method (Fig. 3).
We  also  analyzed  the  correlation  between  the 
expressions  of  stem  cell  related  genes  analyzed. 
A statistically significant positive statistical correlation expression of stem cell related genes in eScc patients
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was observed between the expression of Oct-4 and 
Sox-2 (P = 0.009) indicating that their coexpression 
may play an important role in development of esoph-
ageal tumorigenesis.
Discussion
The self renewal and pluripotency are the hallmarks 
of the embryonic stem cells and it has been observed 
that deregulation of these pathways involved in dif-
ferentiation and maintenance of proliferation. Oct-4, 
Sox-2 and Nanog render the reprogramming capa-
bility of adult cells into induced pluripotent cells.29–31 
Recently, the expression of the genes Oct-4, Sox-2 
and Nanog has been reported in various cancers sug-
gesting  the  tumorigenic  potential  of  these  genes. 
Bmi-1, the first PcG protein found, is a chromatin 
modifier  implicated  in  the  tumorigenesis  through 
negatively regulating the gene expression such as 
the INK4 A locus, which is thought to regulate p53 
and the Rb signaling pathway in cooperation with 
c-myc.32–35
The present investigation on esophageal squamous 
cell carcinomas revealed several interesting observa-
tions. Firstly, it was observed that 92%, 95%, 67%, 
75% of ESCC tissues showed increased expression of 
Oct-4, Sox-2, Nanog and Bmi-1 respectively. Sec-
ondly, most of the preneoplastic tissues were observed 
to be positive for the expression of these genes sug-
gesting their role in early stages of esophageal tum-
origenesis. Thirdly, a significant positive correlation 
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Figure 2. histogram showing the expression levels of stem cell related genes relative to β-actin expression in representative esophageal tissues using 
densitometric analysis of rT-Pcr products (A) shows the relative expression of Oct-4 in 4 distant normals (n1-n4) and 4 eScc tissues (c1-c4). (B) shows 
the relative expression of Sox-2 in 4 distant normals (n1-n4) and 4 eScc tissues (c1-c4) (c) shows the relative expression of nanog in 4 distant normals 
(n1-n4) and 4 eScc tissues (c1-c4) (D) shows the relative expression of Bmi-1 in 3 distant normals (n1-n3) and 3 eScc tissues (c1-c3).Bahl et al
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was observed between the expression of Oct-4 and 
Sox-2 genes (**P = 0.009). Fourthly, to the best of 
our knowledge this is the first study showing the ele-
vated circulating levels of the mRNAs for these genes 
in the sera of the patients showing evidence of hyper-
plasia, dysplasia and ESCC indicating the possible 
potential of these markers to be used in noninvasive 
blood based diagnosis of the disease.
Oct3/4 expression has been studied earlier also in 
the case of many cancers and has shown significant 
expression in many other cancer types like the human 
breast cancer,36 liver, pancreas, kidneys, mesenchyme, 
gastric stem cells,37 HeLa37 and MCF-738 cancer cell 
lines. Oct-4 has also been shown to be highly expressed 
in the bladder cancer.39 Moreover, ectopic expression 
of Oct-4 in heterologous cell system has been shown 
to transform nontumorigenic cells and induces tum-
origenecity in nude mice, implicating its possible role 
in neoplastic process.40 Recently, Qi Wang et al, 2009 
have  shown  Oct-4  protein  expression  in  17.9%  of 
ESCC patients to be associated with higher histologi-
cal grade and poorer clinical survival.41 The elevated 
expression of Oct-4 observed in 92% of ESCCs and 
62.5%  of  preneoplastic  esophageal  lesions  in  the 
present study emphasizes its role in early stages of 
esophageal tumoriogenesis. Interestingly, 12/17 (70%) 
of  the  ESCC  sera  samples  showed  expression  of 
Oct-4 mRNA as compared to no detectable expres-
sion in sera of normal subjects. The presence of this 
stem cell marker in the sera of the patients showing 
evidence of dysplasia and hyperplasia implicates its 
possible potential as a marker for noninvasive early 
diagnosis of this disease. Earlier, Oct-4   overexpression 
has been shown to be positively associated with the 
recurrence in patients with preoperative CRT in rectal 
carcinoma by Saigusa et al 2009.42 Thus, further anal-
ysis of Oct-4 expression in sera of patients who have 
been  given  CRT  can  be  carried  out  to  analyze  its 
potential  as  a  noninvasive  marker  for  monitoring 
relapse and response to therapy.
Sox-2,  the  master  of  pluripotency  control  has 
recently been identified as a novel major oncogene 
recurrently amplified and activated in the squamous 
cell  carcinoma.  These  studies  have  used  a  similar 
strategy  of  chromosomal  aberrations  screening  to 
identify the Sox-2 locus alone of the most frequently 
amplified site over the SCC genome. It has been fur-
ther highlighted by Hussenet et al 2010 that the recur-
rent  Sox-2  activation  and  its  necessary  role  for 
squamous cell carcinoma survival.43 Finally, Yun Lu 
et al 2009 showed that Sox-2 is also involved in the 
early steps of lung SCC, as participating to transform 
human bronchialepithelial cells.44 Furthermore, Sox-2 
overexpression  can  induce  the  expression  of  the 
squamous markers p63 and keratin 6, supporting the 
idea  that  Sox2  might  be  implicated  in  SCC 
  differentiation.45 Sox-2 has been found to be an immu-
nogenic  antigen  in  41%  of  small  cell  lung  cancer 
patients46  and  in  29%  of  meningioma  patients.47 
Immunohistochemistry results suggest that Sox-2 is 
involved in later events of carcinogenesis, such as 
invasion and metastasis of pancreatic intraepithelial 
neoplasia.48 Sox-2 may also be involved in gastric 
carcinogenesis49  and  may  be  amplified  in  prostate 
cancers.50   Furthermore, Sox-2 expression has been 
observed in 43% of basal cell-like breast carcinomas 
and was found to be strongly correlated with CK5/6, 
EGFR, and vimentin immunoreactivity, suggesting 
that Sox-2 may play a role in conferring a less dif-
ferentiated phenotype in these tumors.11 The genomic 
peak amplification of the 3q26.33 found in SCC is 
also found in ESCC and contains the transcription 
factor Sox-2 which is mutated and responsible for 
the hereditary malformations. In the present study the 
elevated expression of Sox-2 was found in 95% cases 
and moreover, the expression of Sox-2 is mainly in 
the cancerous tissues it is either very low or absent in 
distant normals. Our results are in accordance with 
the  latest  study  of  Qi  Wang  et  al  2009  in  which 
22.84% patients showed elevated results.41 The study 
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Figure  3. histogram showing the expression levels of stem cell related 
genes Oct-4, Sox-2, nanog and Bmi-1 expression in representative esopha-
geal tissues using quantitative real time PCR. ∆ct = cttarget gene − ctreference gene.expression of stem cell related genes in eScc patients
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can be further carried out in order to see the stable 
expression  of  Sox-2  in  the  radioresistant  and 
chemoresistant cells. This will corroborate the onco-
genic potential further.
Nanog another transcription factor which plays 
an important role in maintain the pluripotency of 
the embryonic stem cells and it has been found that 
it has strong correlation with Sox-2 and Oct-4 in its 
  expression. The expression of Nanog has been stud-
ied in many cancers including the colorectal cancer 
in which it shows higher expression in a significant 
number of patients and is associated with poor prog-
nosis, lymph node metastasis and invasion. Nanog 
has also been associated with OSCC.51 To the best 
of our knowledge, present study is the first report 
showing  the  increased  expression  of  Nanog  in 
esophageal  squamous  cell  carcinomas  67%.  Ele-
vated levels of circulating Nanog mRNA in the sera 
of the cancer patients observed for the first time in 
the present study may also implicate its potential as 
noinvasive biomarker with 10/17 (60%) of the cases 
showing  expression  of  this  transcript  which  is 
entirely absent from the normal sera. However, the 
results need to be corroborated in larger cohort of 
patients.
Bmi1 mRNA expression was 75% in the ESCC 
samples. The level of Bmi1 mRNA expression was 
found to be elevated in all the dysplastic and hyper-
plastic tissue samples analyzed along with true carci-
nomas. This indicated that Bmi1 plays an important 
role in the initial stages of development of ESCC, 
and may be of diagnostic value. However, its expres-
sion needs to be validated in a larger cohort for better 
understanding of clinical significance of its expres-
sion in ESCCs. The Bmi1 mRNA expression was 
also found to be elevated in some sera samples of 
ESCC patients as compared to normal sera, the per-
centage  of  sera  samples  with  elevated  expression 
was less than 50%, and this could be due to the low 
presence  of  circulating  Bmi1  mRNA  in  ESCC 
patients or due to the low levels of total circulating 
mRNAs in sera.
conclusion
In conclusion, overexpression of stemness markers 
in preneoplastic esophageal tissues and ESCCs as 
compared to non-malignant esophageal epithelium 
suggests  that  they  may  serve  as  a  candidate 
molecular target for early detection of esophageal 
cancer.   Esophageal cancer patients often report to 
the clinics in advanced stages of the disease (often 
inoperable  due  to  extensive  metastasis);  hence 
availability of clinical human specimens in early 
stages of the disease (dysplasia and hyperplasia) is 
severely limited. In view of these constraints the 
present study is of great significance. However, in-
depth  studies  are  warranted  to  determine  their 
potential as candidate molecular markers for esoph-
ageal cancer.   Furthermore, the detection of elevated 
levels of circulating mRNAs of Oct-4 (70%) and 
Nanog (60%) in sera of esophageal cancer patients 
indicates  their  potential  as  minimally  invasive 
diagnostic markers for esophageal cancer. Hence, 
the present study undertaken may open new ave-
nues  for  in  depth  analysis  and  validation  of  the 
stem cell related genes, studied herein, as potential 
diagnostic tools for the identification of esophageal 
squamous cell carcinoma at early stages to improve 
its prognosis.
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